Pharma BD Deal Intelligence

GSK plc / Halozyme Therapeutics, Inc.

2026 · Licensing/Option · Complete

Halozyme Therapeutics announced a global collaboration and license agreement giving GSK access to Halozyme's ENHANZE drug delivery technology to develop and potentially commercialize subcutaneous formulations of multiple oncology targets, including antibody-drug conjugates. It is Halozyme's first ENHANZE agreement to include ADC targets, and GSK also received an option on additional future targets. GSK pays an undisclosed upfront payment, with potential milestone payments and royalties on net sales of ENHANZE-enabled products. The first clinical trial under the collaboration was projected to start in 2026. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  GSK plc deals